p53 regulates the mevalonate pathway in human glioblastoma multiforme

被引:38
|
作者
Laezza, C. [1 ]
D'Alessandro, A. [2 ,3 ]
Di Croce, L. [4 ]
Picardi, P. [2 ,3 ]
Ciaglia, E. [2 ,3 ]
Pisanti, S. [2 ,3 ]
Malfitano, A. M. [2 ,3 ]
Comegna, M. [5 ,6 ]
Faraonio, R. [5 ,6 ]
Gazzerro, P. [2 ,3 ]
Bifulco, M. [2 ,3 ]
机构
[1] IEOS CNR, Inst Endocrinol & Expt Oncol, Naples, Italy
[2] Univ Salerno, Dept Med & Surg, I-84081 Baronissi, SA, Italy
[3] Univ Salerno, Dept Pharm, Fisciano, Italy
[4] Univ Pompeu Fabra, CRG, Barcelona, Spain
[5] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy
[6] Biotecnol Avanzate, CEINGE, Naples, Italy
来源
CELL DEATH & DISEASE | 2015年 / 6卷
关键词
COENZYME-A REDUCTASE; LIPID-METABOLISM; GENE-EXPRESSION; CANCER-CELLS; CHOLESTEROL; INHIBITION; GROWTH; SENSITIVITY; CARCINOMA; PROMOTES;
D O I
10.1038/cddis.2015.279
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The mevalonate (MVA) pathway is an important metabolic pathway implicated in multiple aspects of tumorigenesis. In this study, we provided evidence that p53 induces the expression of a group of enzymes of the MVA pathway including 3'-hydroxy-3'-methylglutaryl-coenzyme A reductase, MVA kinase, farnesyl diphosphate synthase and farnesyl diphosphate farnesyl transferase 1, in the human glioblastoma multiforme cell line, U343 cells, and in normal human astrocytes, NHAs. Genetic and pharmacologic perturbation of p53 directly influences the expression of these genes. Furthermore, p53 is recruited to the gene promoters in designated p53-responsive elements, thereby increasing their transcription. Such effect was abolished by site-directed mutagenesis in the p53-responsive element of promoter of the genes. These findings highlight another aspect of p53 functions unrelated to tumor suppression and suggest p53 as a novel regulator of the MVA pathway providing insight into the role of this pathway in cancer progression.
引用
收藏
页码:e1909 / e1909
页数:10
相关论文
共 50 条
  • [21] Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway
    Freed-Pastor, William A.
    Mizuno, Hideaki
    Zhao, Xi
    Langerod, Anita
    Moon, Sung-Hwan
    Rodriguez-Barrueco, Ruth
    Barsotti, Anthony
    Chicas, Agustin
    Li, Wencheng
    Polotskaia, Alla
    Bissell, Mina J.
    Osborne, Timothy F.
    Tian, Bin
    Lowe, Scott W.
    Silva, Jose M.
    Borresen-Dale, Anne-Lise
    Levine, Arnold J.
    Bargonetti, Jill
    Prives, Carol
    CELL, 2012, 148 (1-2) : 244 - 258
  • [22] p53 regulates apoptosis in human retinoblastoma
    Nork, TM
    Poulsen, GL
    Millecchia, LL
    Jantz, RG
    Nickells, RW
    ARCHIVES OF OPHTHALMOLOGY, 1997, 115 (02) : 213 - 219
  • [23] MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer
    Yu-kun Zheng
    Zhong-shi Zhou
    Guang-zhong Wang
    Ji-yuan Tu
    Huan-bo Cheng
    Shang-zhi Ma
    Chang Ke
    Yan Wang
    Qi-pan Jian
    Yu-hang Shu
    Xiao-wei Wu
    Cell Death & Disease, 14
  • [24] MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer
    Zheng, Yu-kun
    Zhou, Zhong-shi
    Wang, Guang-zhong
    Tu, Ji-yuan
    Cheng, Huan-bo
    Ma, Shang-zhi
    Ke, Chang
    Wang, Yan
    Jian, Qi-pan
    Shu, Yu-hang
    Wu, Xiao-wei
    CELL DEATH & DISEASE, 2023, 14 (04)
  • [25] Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme
    Feng, Yuxin
    Wang, Yingjie
    Li, Xiaoxue
    Sun, Ziqiang
    Qiang, Sihan
    Wang, Hongbo
    Liu, Yi
    MOLECULES, 2024, 29 (10):
  • [26] Abnormal p53 expression and radiographically assessed radiation response in glioblastoma multiforme (GM).
    Simmons, ML
    Barker, FG
    Prados, MD
    Chang, SM
    Lamborn, KR
    Wara, WM
    Sneed, PK
    Larson, DA
    Bollen, AW
    Davis, RL
    Wilson, CB
    Berger, MS
    Chen, P
    Aldape, K
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (05): : 470 - 470
  • [27] Low dose of wortmannin reduces radiosensitivity of human glioblastoma cells through the p53 pathway
    Okaichi, K
    Suzuki, K
    Morita, N
    Ikeda, M
    Takahashi, H
    Matsuda, N
    Watanabe, M
    Okumura, Y
    ONCOLOGY REPORTS, 2002, 9 (04) : 859 - 862
  • [28] Beyond the Mevalonate Pathway: Control of Post-Prenylation Processing by Mutant p53
    Borini Etichetti, Carla M.
    Arel Zalazar, Evelyn
    Cocordano, Nabila
    Girardini, Javier
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [29] ACTIVATION OF P53 BY MDM2 ANTAGONISTS DOWN-REGULATES SURVIVIN AND INDUCES CELL-CYCLE ARREST AND APOPTOSIS IN HUMAN GLIOBLASTOMA MULTIFORME
    Villalonga, R.
    Coll-Mulet, L.
    Martinez-Soler, F.
    Castano, E.
    Acebes, J.
    Gimenez-Bonafe, P.
    Gil, J.
    Tortosa, A.
    NEURO-ONCOLOGY, 2010, 12 : 50 - 50
  • [30] The P53 pathway
    Prives, C
    Hall, PA
    JOURNAL OF PATHOLOGY, 1999, 187 (01): : 112 - 126